Johnson & Johnson reported better-than-expected Q2 2026 results with adjusted EPS of $2.90, surpassing estimates, and revenue of $25.31 billion, driven by strong pharmaceutical sales. Key growth came from the Innovative Medicine segment, with notable sales from Tremfya and Darzalex offsetting patent losses on older drugs. The company raised its full-year 2026 guidance to $100.8-$101.4 billion in sales and adjusted EPS of $11.60-$11.75. CEO Joaquin Duato highlighted recent product approvals and a strong innovation pipeline, signaling confidence in reaching over $100 billion in annual revenue for the first time in its history.
Johnson & Johnson announced positive Phase 2b COPERNICUS study results showing low rates of rash, blood clots, and administration-related reactions with subcutaneous RYBREVANT FASPRO plus LAZCLUZE in treating advanced non-small cell lung cancer with ...
Johnson & Johnson announced that RYBREVANT combined with chemotherapy significantly improved overall survival in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. The Phase 3 PAPILLON study showed a...
Five Dividend Kings—Procter & Gamble, Johnson & Johnson, Lowe’s, Emerson Electric, and Genuine Parts Company—are highlighted as top income stocks for retirees due to their decades-long records of annual dividend increases. These companies have mainta...
The iShares U.S. Pharmaceuticals ETF (IHE) provides focused exposure to the US pharmaceutical sector, heavily weighted towards Johnson & Johnson and Eli Lilly. It benefits from growth drivers like obesity therapies and strong drug pipelines but carri...
Five dividend stocks—Procter & Gamble, Johnson & Johnson, Coca-Cola, Colgate-Palmolive, and PepsiCo—have consistently raised their dividends through every U.S. recession since at least 1963. These companies demonstrated resilience during major downtu...
